Clinical trials
Myotonic Dystrophy trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
42 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2005 | 1 |
| 2007 | 1 |
| 2011 | 1 |
| 2013 | 5 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 4 |
| 2022 | 6 |
| 2023 | 4 |
| 2024 | 3 |
| 2025 | 6 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 19 |
| Completed | 15 |
| Enrolling by invitation | 4 |
| Active, not recruiting | 2 |
| Unknown status | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| University of Rochester | 6 |
| Virginia Commonwealth University | 6 |
| Avidity Biosciences, Inc. | 4 |
| Massachusetts General Hospital | 4 |
| Dyne Therapeutics | 3 |
| AMO Pharma Limited | 2 |
| Stanford University | 2 |
| Vertex Pharmaceuticals Incorporated | 2 |
| Wake Forest University Health Sciences | 2 |
| ARTHEx Biotech S.L. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Myotonic Dystrophy | 42 |
| Muscular Dystrophies | 12 |
| Myotonic Disorders | 9 |
| Myotonia | 7 |
| Neuromuscular Diseases | 7 |
| Genetic Diseases, Inborn | 5 |
| Neurodegenerative Diseases | 5 |
| Heredodegenerative Disorders, Nervous System | 4 |
| Muscular Diseases | 4 |
| Muscular Disorders, Atrophic | 4 |
Trials
Showing 1 to 25 of 42. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.